PF-05388169

CAS No. 1604034-78-7

PF-05388169( PF 05388169 | PF05388169 )

Catalog No. M12302 CAS No. 1604034-78-7

A potent, selective IRAK4 inhibitor with IC50 of 0.094 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 873 Get Quote
50MG 1782 Get Quote
100MG 2250 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    PF-05388169
  • Note
    Research use only, not for human use.
  • Brief Description
    A potent, selective IRAK4 inhibitor with IC50 of 0.094 nM.
  • Description
    A potent, selective IRAK4 inhibitor with IC50 of 0.094 nM, >500-fold selectivity over IRAK1 (IC50=65 nM); exhibits low nM potency in LPS- and R848-induced cytokine assays (IC50=85 nM) in human PBMCs; inhibits LPS-induced TNFα in an in vivo murine model.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    PF 05388169 | PF05388169
  • Pathway
    Immunology/Inflammation
  • Target
    IRAK
  • Recptor
    IRAK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1604034-78-7
  • Formula Weight
    391.427
  • Molecular Formula
    C22H21N3O4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    N#CC1=CC(N2)=C(C3=C2C4=CC(OC)=C(OCCOCCOC)C=C4N=C3)C=C1
  • Chemical Name
    11H-Indolo[3,2-c]quinoline-9-carbonitrile, 2-methoxy-3-[2-(2-methoxyethoxy)ethoxy]-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Lai CY, et al. J Immunol Res. 2017;2017:7807313.
molnova catalog
related products
  • PF-05387252

    A potent, selective IRAK4 inhibitor with IC50 of 1.3 nM, 200-fold selectivity over IRAK1 (IC50=290 nM).

  • PF-06650833

    PF-06650833 (PF06650833) is a potent and selective IRAK4 inhibitor with IC50 of 0.2 nM.

  • Zabedosertib

    Zabedosertib (BAY 1834845) is an inhibitor of IRAK4 with immunomodulatory potential. Zabedosertib protects against acute respiratory distress syndrome, a new study suggests.